Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 6/20 | 0.51 |
| ▸ | USP30 | Q70CQ3 | 3/20 | 0.48 |
| ▸ | JAK2 | O60674 | 1/20 | 0.45 |
| ▸ | JAK1 | P23458 | 1/20 | 0.45 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.43 |
| ▸ | EGFR | P00533 | 2/20 | 0.43 |
| ▸ | BRD4 | O60885 | 1/20 | 0.41 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.41 |
| ▸ | PARP1 | P09874 | 1/20 | 0.41 |
| ▸ | JAK3 | P52333 | 2/20 | 0.40 |
| ▸ | SRC | P12931 | 1/20 | 0.40 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.40 |
| ▸ | BCHE | P06276 | 1/20 | 0.40 |
| ▸ | HTR6 | P50406 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16320728 | 1.00 | BTK (0.51) | BTKUSP30JAK2JAK1PIK3CD | |
| SCHEMBL15143899 | 0.95 | BTK (0.57) | BTKUSP30JAK2JAK1PIK3CD | |
| SCHEMBL15710701 | 0.95 | BTK (0.57) | BTKUSP30JAK2JAK1PIK3CD | |
| SCHEMBL14798056 | 0.91 | BTK (0.47) | BTKUSP30JAK2JAK1PIK3CD | |
| SCHEMBL31626228 | 0.91 | BTK (0.47) | BTKUSP30JAK2JAK1PIK3CD | |
| SCHEMBL15155924 | 0.88 | BTK (0.45) | BTKJAK1EGFRJAK3 | |
| SCHEMBL16341281 | 0.87 | BTK (0.47) | BTKUSP30JAK2JAK1PIK3CD | |
| SCHEMBL15156453 | 0.87 | BTK (0.47) | BTKUSP30JAK2JAK1PIK3CD | |
| SCHEMBL18645214 | 0.87 | USP30 (0.48) | BTKUSP30JAK2JAK1BRD4 | |
| SCHEMBL30760937 | 0.85 | JAK2 (0.45) | BTKUSP30JAK2JAK1EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3147285-A2 | PURINONE COMPOUNDS AS KINASE INHIBITORS | Pharmacyclics, Inc. (US) | 2017-03-29 | — | — | EP | disclosed |
| US-20160368924-A1 | PURINONE COMPOUNDS AS KINASE INHIBITORS | PHARMACYCLICS, INC. | 2016-12-22 | — | — | US | disclosed |
| US-9469642-B2 | Purinone compounds as kinase inhibitors | PHARMACYCLICS LLC (US) | 2016-10-18 | — | — | US | disclosed |
| US-20140378446-A1 | PURINONE COMPOUNDS AS KINASE INHIBITORS | PHARMACYCLICS, INC. (US) | 2014-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160368924-A1 | PURINONE COMPOUNDS AS KINASE INHIBITORS | BTK, LCK, BCL9 | BTK 1/4885USP30 2023/4885JAK2 8/4885 |
| US-20140378446-A1 | PURINONE COMPOUNDS AS KINASE INHIBITORS | BTK, LCK, BCL9 | BTK 1/4885USP30 2023/4885JAK2 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.